Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity
Tyrosine kinase inhibitors (TKIs) have emerged as the preferred choice of treatment for various tumors as a result of better outcomes and quality of life without the debilitating side effects of cytotoxic chemotherapy. Erlotinib is a TKI against epidermal growth factor receptor that is commonly used...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | Journal of Radiation and Cancer Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jrcr.jrcr_12_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839637826955640832 |
|---|---|
| author | Aashita Vikas Yadav Pragyat Thakur Anuja Kapoor |
| author_facet | Aashita Vikas Yadav Pragyat Thakur Anuja Kapoor |
| author_sort | Aashita |
| collection | DOAJ |
| description | Tyrosine kinase inhibitors (TKIs) have emerged as the preferred choice of treatment for various tumors as a result of better outcomes and quality of life without the debilitating side effects of cytotoxic chemotherapy. Erlotinib is a TKI against epidermal growth factor receptor that is commonly used in lung cancer and pancreatic cancer. The most common adverse effect expected is cutaneous toxicity, which occurs as acneiform rash. Here, we present a case of 71-year-old man with metastatic lung cancer who had an atypical squamous-crusted eruption with intense itching and pain on his forehead that resolved spontaneously after withholding erlotinib along with supportive care. The present case depicts unusual cutaneous toxicity with the use of TKI. |
| format | Article |
| id | doaj-art-d8c2316ee6f1441c95fb81b58eb509d0 |
| institution | Matheson Library |
| issn | 2588-9273 2468-9203 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Radiation and Cancer Research |
| spelling | doaj-art-d8c2316ee6f1441c95fb81b58eb509d02025-07-06T07:53:01ZengWolters Kluwer Medknow PublicationsJournal of Radiation and Cancer Research2588-92732468-92032025-04-01162899210.4103/jrcr.jrcr_12_24Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous ToxicityAashitaVikas YadavPragyat ThakurAnuja KapoorTyrosine kinase inhibitors (TKIs) have emerged as the preferred choice of treatment for various tumors as a result of better outcomes and quality of life without the debilitating side effects of cytotoxic chemotherapy. Erlotinib is a TKI against epidermal growth factor receptor that is commonly used in lung cancer and pancreatic cancer. The most common adverse effect expected is cutaneous toxicity, which occurs as acneiform rash. Here, we present a case of 71-year-old man with metastatic lung cancer who had an atypical squamous-crusted eruption with intense itching and pain on his forehead that resolved spontaneously after withholding erlotinib along with supportive care. The present case depicts unusual cutaneous toxicity with the use of TKI.https://journals.lww.com/10.4103/jrcr.jrcr_12_24acneiform rashcutaneous side effectepidermal growth factor receptor inhibitorerlotinib |
| spellingShingle | Aashita Vikas Yadav Pragyat Thakur Anuja Kapoor Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity Journal of Radiation and Cancer Research acneiform rash cutaneous side effect epidermal growth factor receptor inhibitor erlotinib |
| title | Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity |
| title_full | Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity |
| title_fullStr | Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity |
| title_full_unstemmed | Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity |
| title_short | Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity |
| title_sort | unusual cutaneous reaction with erlotinib a brief report with current review of management of tyrosine kinase inhibitor associated cutaneous toxicity |
| topic | acneiform rash cutaneous side effect epidermal growth factor receptor inhibitor erlotinib |
| url | https://journals.lww.com/10.4103/jrcr.jrcr_12_24 |
| work_keys_str_mv | AT aashita unusualcutaneousreactionwitherlotinibabriefreportwithcurrentreviewofmanagementoftyrosinekinaseinhibitorassociatedcutaneoustoxicity AT vikasyadav unusualcutaneousreactionwitherlotinibabriefreportwithcurrentreviewofmanagementoftyrosinekinaseinhibitorassociatedcutaneoustoxicity AT pragyatthakur unusualcutaneousreactionwitherlotinibabriefreportwithcurrentreviewofmanagementoftyrosinekinaseinhibitorassociatedcutaneoustoxicity AT anujakapoor unusualcutaneousreactionwitherlotinibabriefreportwithcurrentreviewofmanagementoftyrosinekinaseinhibitorassociatedcutaneoustoxicity |